A Phase 2 interventional study of Momelotinib in Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by Sierra Oncology LLC - a GSK company. Completed at 22 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing momelotinib in Primary Myelofibrosis — 3 open to participants now, 4 under way, none of them phase 3. momelotinib · Primary Myelofibrosis.
Among the 12 studies testing momelotinib in Primary Myelofibrosis, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 6th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →3 of the 12 studies testing momelotinib in Primary Myelofibrosis are open now, in 6 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
GlaxoSmithKline · Sites in United States, Canada, France and 3 more countries
Ages 18+
SWOG Cancer Research Network
Ages 18+
By country, each count listing its studies:
momelotinib: first FDA approval 2023 (OJJAARA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 3 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 138 across the 12 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Sierra Oncology LLC - a GSK company, one of the names counted as GlaxoSmithKline. Under that name alone:
Sierra Oncology LLC - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
11 studies in Primary Myelofibrosis by GlaxoSmithKline: 1 open now, 2 under way, none of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 11 studies in Primary Myelofibrosis by GlaxoSmithKline, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 6th registered.
GlaxoSmithKline’s Primary Myelofibrosis studies by the year they started, since 2009.
2 of the studies testing momelotinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03441113GlaxoSmithKlineExtended Access of Momelotinib in Adults With Myelofibrosis | 2026-12-11 |
| NCT06517875GlaxoSmithKlineStudy of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | 2027-03-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing momelotinib in Primary Myelofibrosis, from their registry updates:
Among GlaxoSmithKline’s 11 in Primary Myelofibrosis:
This tab as a report to print or save as PDF → With an account.
This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved stable disease or better with momelotinib treatment while enrolled in a previous clinical trial.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
Drug: Momelotinib
Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
Drug: Momelotinib
Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years. Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated.
Drug: Momelotinib
Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
Drug: Momelotinib
Momelotinib tablets administered orally once daily
Also known as: GS-0387, CYT387
Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities
Long-term safety and tolerability profile of momelotinib based on safety data (adverse events and selected hematology and chemistry laboratory parameters) collected after the first dose of momelotinib in the parent study.
Time frame: From the first dose of momelotinib in the parent study to 30 days following permanent discontinuation of momelotinib in Study GS-US-352-1154.
Splenic Response Rate
The number of subjects achieving a spleen response, defined as a reduction of 50% or more in palpable splenomegaly of a spleen that was at least 10 cm below the LCM at baseline, or a spleen that was palpable at \> 5 cm and \< 10 cm below the LCM at baseline becoming not palpable for at least 56 days, using baseline of the parent study as the reference.
Time frame: From baseline in the parent study until the last spleen assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Duration of Splenic Response
The interval from the first onset of splenic response (in the parent study or Study GS-US-352-1154) to the earliest date of loss of splenic response. Loss of response was defined as the reduction of splenomegaly by \< 50% among responders (with splenomegaly ≥ 10 cm below the LCM at baseline) that lasts ≥ 56 days, or the recurrence of \> 0 cm splenomegaly among responders (with splenomegaly \> 5 and \< 10 cm at baseline) that lasts ≥ 56 days. Duration of splenic response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.
Time frame: From baseline in the parent study until the last spleen assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Transfusion Independence Response Rate
The number of transfusion dependent subjects at entry to a parent study who became transfusion-independent for ≥ 12 weeks at any time from the first dose of momelotinib in the parent study until the end of Study GS-US-352-1154.
Time frame: From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Duration of Transfusion Independence Response
The interval from the first onset date of transfusion independence (in the parent study or Study GS-US-352-1154) to the earliest date of loss of response for participants who are transfusion dependent at baseline in the parent study. Loss of TI response was defined as receiving an RBC transfusion after achieving a TI response. Duration of transfusion independence response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.
Time frame: From baseline in the parent study until the last assessment date in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Anemia Response Rate
The number of subjects achieving an anemia response, defined as: * Achieving transfusion independence for ≥ 12 weeks, for subjects who were transfusion-dependent at baseline in the parent study, or * Having ≥ 2 g/dL increase in Hgb from baseline for ≥ 12 weeks, for subjects with Hgb \< 10 g/dL at baseline in the parent study who were not transfusion-dependent (Cohort 1) or who were transfusion-independent (Cohort 2).
Time frame: From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Duration of Anemia Response
The interval from the first onset of anemia response (in the parent study or Study GS-US-352-1154) to the earliest date of loss of anemia response. Loss of anemia response was defined as having any RBC transfusion after achieving an anemia response. Duration of anemia response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.
Time frame: From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Rate of RBC Transfusion
The average number of RBC units per subject month during the parent study and/or Study GS-US-352-1154.
Time frame: From the first dose of momelotinib in the parent study until the last dose of momelotinib in Study GS-US-352-1154.
Overall Survival
The interval from the first dose of momelotinib in the parent study until death from any cause. Overall survival was analyzed using the Kaplan-Meier method. Data from subjects who were lost to follow-up or remained alive until the end of the study were censored at the date of last contact or last response assessment.
Time frame: From baseline in the parent study until the date of last contact or last response assessment, up to 30 days following permanent discontinuation of momelotinib.
Progression-Free Survival
The interval from the first dose of momelotinib in the parent study until the first documentation of definitive progressive disease as defined in 2006 IWG-MRT or death due to any cause. Subjects who were free of progression were censored at the last assessment date.
Time frame: From baseline in the parent study until the last response assessment, up to 30 days following permanent discontinuation of momelotinib.
Leukemia-Free Survival
The interval from the first dose of momelotinib in the parent study until the first documented leukemic transformation or death from any cause. Leukemic transformation was documented in the adverse event electronic case report form. Leukemia-free survival was analyzed using the Kaplan-Meier method. Subjects who were free of leukemia transformation were censored at the last assessment date.
Time frame: From baseline in the parent study until the date of the last assessment, up to 30 days following permanent discontinuation of momelotinib.
Benefiting subjects enrolled in 1 of 3 prior momelotinib (MMB) studies (parent studies) for the treatment of MF were included for continued dosing of MMB. Cohort 3 (PV/ET; n=13) was closed and subjects were discontinued due to limited efficacy of MMB in the treatment of PV/ET observed in the parent study. Cohort 3 was excluded from all analyses.
| Milestone | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) |
|---|---|---|---|
| Started | 30 | 22 | 22 |
| Completed | 11 | 4 | 0 |
| Not completed | 19 | 18 | 22 |
| Withdrew: Adverse event | 2 | 1 | 2 |
| Withdrew: Death | 2 | 1 | 3 |
| Withdrew: Lack of efficacy | 3 | 2 | 2 |
| Withdrew: Physician decision | 6 | 4 | 5 |
| Withdrew: Non-compliance with study drug | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 6 |
| Withdrew: Disease progression | 3 | 6 | 4 |
Long-term safety and tolerability profile of momelotinib based on safety data (adverse events and selected hematology and chemistry laboratory parameters) collected after the first dose of momelotinib in the parent study.
| Participants | Total |
|---|---|
| Subjects with ≥ one AE (any grade) | 73 |
| Subjects with ≥ one Grade 3 or higher AE | 62 |
| Subjects with Grade 3 lab toxicity (highest grade) | 36 |
| Subjects with Grade 4 lab toxicity (highest grade) | 16 |
The number of subjects achieving a spleen response, defined as a reduction of 50% or more in palpable splenomegaly of a spleen that was at least 10 cm below the LCM at baseline, or a spleen that was palpable at \> 5 cm and \< 10 cm below the LCM at baseline becoming not palpable for at least 56 days, using baseline of the parent study as the reference.
| Participants | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Splenic Response Rate | 20 | 19 | 6 | 45 |
The interval from the first onset of splenic response (in the parent study or Study GS-US-352-1154) to the earliest date of loss of splenic response. Loss of response was defined as the reduction of splenomegaly by \< 50% among responders (with splenomegaly ≥ 10 cm below the LCM at baseline) that lasts ≥ 56 days, or the recurrence of \> 0 cm splenomegaly among responders (with splenomegaly \> 5 and \< 10 cm at baseline) that lasts ≥ 56 days. Duration of splenic response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.
| days | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Duration of Splenic Response | 1704.5 (1153.5 to 2682.0) | 736.0 (197.0 to 1070.0) | 447.5 (128.0 to 758.0) | 990.0 (226.0 to 1802.0) |
The number of transfusion dependent subjects at entry to a parent study who became transfusion-independent for ≥ 12 weeks at any time from the first dose of momelotinib in the parent study until the end of Study GS-US-352-1154.
| Participants | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Transfusion Independence Response Rate | 7 | 5 | 16 | 28 |
The interval from the first onset date of transfusion independence (in the parent study or Study GS-US-352-1154) to the earliest date of loss of response for participants who are transfusion dependent at baseline in the parent study. Loss of TI response was defined as receiving an RBC transfusion after achieving a TI response. Duration of transfusion independence response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.
| days | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Duration of Transfusion Independence Response | 357.0 (117.0 to 1841.0) | 114.0 (95.0 to 126.0) | 281.5 (110.0 to 633.5) | 193.5 (110.0 to 701.0) |
The number of subjects achieving an anemia response, defined as: * Achieving transfusion independence for ≥ 12 weeks, for subjects who were transfusion-dependent at baseline in the parent study, or * Having ≥ 2 g/dL increase in Hgb from baseline for ≥ 12 weeks, for subjects with Hgb \< 10 g/dL at baseline in the parent study who were not transfusion-dependent (Cohort 1) or who were transfusion-independent (Cohort 2).
| Participants | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Anemia Response Rate | 13 | 6 | 16 | 35 |
The interval from the first onset of anemia response (in the parent study or Study GS-US-352-1154) to the earliest date of loss of anemia response. Loss of anemia response was defined as having any RBC transfusion after achieving an anemia response. Duration of anemia response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.
| days | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Duration of Anemia Response | 995.0 (297.0 to 1841.0) | 120.0 (95.0 to 744.0) | 281.5 (110.0 to 633.5) | 358.0 (114.0 to 954.0) |
The average number of RBC units per subject month during the parent study and/or Study GS-US-352-1154.
| RBC units per month | Total |
|---|---|
| RBC Transfusion Rate in Parent Studies | 0.08 (0.0 to 5.4) |
| RBC Transfusion Rate in Study GS-US-352-1154 | 0.00 (0.0 to 4.8) |
| RBC Transfusion Rate Since 1st Dose in ParentStudy | 0.06 (0.0 to 4.9) |
The interval from the first dose of momelotinib in the parent study until death from any cause. Overall survival was analyzed using the Kaplan-Meier method. Data from subjects who were lost to follow-up or remained alive until the end of the study were censored at the date of last contact or last response assessment.
| months | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Overall Survival | NA (36.7 to 99.6) | NA (28.1 to 81.6) | NA (6.3 to 29.6) | NA (6.3 to 99.6) |
The interval from the first dose of momelotinib in the parent study until the first documentation of definitive progressive disease as defined in 2006 IWG-MRT or death due to any cause. Subjects who were free of progression were censored at the last assessment date.
| months | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Progression-Free Survival | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The interval from the first dose of momelotinib in the parent study until the first documented leukemic transformation or death from any cause. Leukemic transformation was documented in the adverse event electronic case report form. Leukemia-free survival was analyzed using the Kaplan-Meier method. Subjects who were free of leukemia transformation were censored at the last assessment date.
| months | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Leukemia-Free Survival | NA (36.7 to 99.6) | NA (28.1 to 81.6) | NA (6.1 to 29.6) | NA (6.1 to 99.6) |
Collected over From the first dose of momelotinib in the parent study until 30 days after the last dose in Study GS-US-352-1154.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total | 8/74 (10.8%) | 49/74 (66.2%) | 73/74 (98.6%) |
| Event | Total |
|---|---|
| PneumoniaInfections and infestations | 7/74 |
| Abdominal painGastrointestinal disorders | 6/74 |
| Acute kidney injuryRenal and urinary disorders | 5/74 |
| Cardiac failure congestiveCardiac disorders | 4/74 |
| Lung infectionInfections and infestations | 4/74 |
| SepsisInfections and infestations | 3/74 |
| Urinary tract infectionInfections and infestations | 3/74 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/74 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/74 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/74 |
| Event | Total |
|---|---|
| DiarrhoeaGastrointestinal disorders | 41/74 |
| FatigueGeneral disorders | 35/74 |
| NauseaGastrointestinal disorders | 33/74 |
| Peripheral sensory neuropathyNervous system disorders | 31/74 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 29/74 |
| ThrombocytopeniaBlood and lymphatic system disorders | 28/74 |
| DizzinessNervous system disorders | 28/74 |
| HeadacheNervous system disorders | 28/74 |
| AnaemiaBlood and lymphatic system disorders | 27/74 |
| Abdominal painGastrointestinal disorders | 23/74 |
| Age, Continuous(years) | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Median | 66.0 (34.0 to 82.0) | 64.0 (48.0 to 80.0) | 68.0 (44.0 to 88.0) | 66.5 (34.0 to 88.0) |
| Sex: Female, Male(Participants) | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Female | 17 | 10 | 9 | 36 |
| Male | 13 | 12 | 13 | 38 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| White | 26 | 20 | 18 | 64 |
| Black or African American | 0 | 2 | 2 | 4 |
| Asian | 2 | 0 | 0 | 2 |
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Other | 1 | 0 | 2 | 3 |
| Transfusion Dependent (at baseline in parent study)(Participants) | Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154) | Cohort 2 (YM387-II-02/GS-US-352-1154) | Cohort 4 (GS-US-352-1672/GS-US-352-1154) | Total |
|---|---|---|---|---|
| Yes | 7 | 7 | 22 | 36 |
| No | 23 | 12 | 0 | 35 |
| Missing | 0 | 3 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2014 to primary completion in Dec 2018, 55 months.
Results were first posted in Feb 2021, 2 years 1 month after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 55 months is above that.
Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Momelotinib
Sierra Oncology LLC - a GSK company →